Graham McIlroy1, Sarah K Thomas2, Jamie J Coleman2. 1. School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. 2. School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK.
Abstract
BACKGROUND: Behavioural and psychological symptoms of dementia are distressing for patients and are frequently treated with second-generation antipsychotics. Concerns about the drugs' safety resulted in a Medicines and Healthcare Products Regulatory Agency (MHRA) warning against their use in March 2009. METHODS: Second-generation antipsychotic drug use was determined amongst patients with dementia admitted to the University Hospitals Birmingham National Health Service Foundation Trust, between July 2005 and December 2011. An interrupted time series analysis was carried out to investigate changes in rates of prescribing following the safety warning. Risperidone was analysed separately, in accordance with its limited licence for use in older adults with dementia, granted in October 2008. RESULTS: Before the safety warning, second-generation antipsychotic use was increasing in patients with dementia. After the MHRA warning, their use fell by 1.9% per month compared with that before. Use of risperidone continued to rise over the same period, often against the terms of its licence. CONCLUSIONS: Drug safety warnings may influence prescribing practice, although continued use of antipsychotics in dementia could reflect a lack of alternative treatment options.
BACKGROUND: Behavioural and psychological symptoms of dementia are distressing for patients and are frequently treated with second-generation antipsychotics. Concerns about the drugs' safety resulted in a Medicines and Healthcare Products Regulatory Agency (MHRA) warning against their use in March 2009. METHODS: Second-generation antipsychotic drug use was determined amongst patients with dementia admitted to the University Hospitals Birmingham National Health Service Foundation Trust, between July 2005 and December 2011. An interrupted time series analysis was carried out to investigate changes in rates of prescribing following the safety warning. Risperidone was analysed separately, in accordance with its limited licence for use in older adults with dementia, granted in October 2008. RESULTS: Before the safety warning, second-generation antipsychotic use was increasing in patients with dementia. After the MHRA warning, their use fell by 1.9% per month compared with that before. Use of risperidone continued to rise over the same period, often against the terms of its licence. CONCLUSIONS: Drug safety warnings may influence prescribing practice, although continued use of antipsychotics in dementia could reflect a lack of alternative treatment options.
Authors: Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: Elizabeth L Sampson; Martin R Blanchard; Louise Jones; Adrian Tookman; Michael King Journal: Br J Psychiatry Date: 2009-07 Impact factor: 9.319
Authors: Helen C Kales; Kara Zivin; Hyungjin Myra Kim; Marcia Valenstein; Claire Chiang; Rosalinda V Ignacio; Rosalindo Ignacio; Dara Ganoczy; Francesca Cunningham; Lon S Schneider; Frederic C Blow Journal: Arch Gen Psychiatry Date: 2011-02
Authors: Susan E Bronskill; Geoffrey M Anderson; Kathy Sykora; Walter P Wodchis; Sudeep Gill; Kenneth I Shulman; Paula A Rochon Journal: J Am Geriatr Soc Date: 2004-05 Impact factor: 5.562
Authors: Annalisa Rubino; Myrlene Sanon; Michael L Ganz; Alex Simpson; Miriam C Fenton; Sumit Verma; Ann Hartry; Ross A Baker; Ruth A Duffy; Keva Gwin; Howard Fillit Journal: JAMA Netw Open Date: 2020-04-01
Authors: S Jill Stocks; Evangelos Kontopantelis; Roger T Webb; Anthony J Avery; Alistair Burns; Darren M Ashcroft Journal: Drug Saf Date: 2017-08 Impact factor: 5.606